GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » Land And Improvements

LTR Pharma (ASX:LTP) Land And Improvements : A$0.00 Mil (As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is LTR Pharma Land And Improvements?

LTR Pharma's land and improvements for the quarter that ended in Jun. 2023 was A$0.00 Mil.


LTR Pharma Land And Improvements Historical Data

The historical data trend for LTR Pharma's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LTR Pharma Land And Improvements Chart

LTR Pharma Annual Data
Trend Jun21 Jun22 Jun23
Land And Improvements
- - -

LTR Pharma Semi-Annual Data
Jun21 Jun22 Jun23
Land And Improvements - - -

LTR Pharma Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.


LTR Pharma (ASX:LTP) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
9A/204 Alice Street, Brisbane, QLD, AUS, 4000
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on market.

LTR Pharma (ASX:LTP) Headlines

No Headlines